Menogaril

Menogaril

Menogaril

Chemical compound

Menogaril is an anthracycline analog of nogalamycin which was developed in late 1970s. It has even stronger anticancer activity than nogalamycin and has less toxicity than nogalamycin. However, its development for clinical use was cancelled due to only moderate success with relatively high incidence of serious toxicity (43-44% in non-Hodgkin's lymphoma patients).[1]

Quick Facts Names, Identifiers ...

References

  1. [1]
    Moore DF Jr; Brown TD; LeBlanc M; Dahlberg S; Miller TP; McClure S; Fisher RI. (1999). "Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial". Invest New Drugs. 17 (2): 169–72. doi:10.1023/A:1006375301205.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Menogaril, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.